Expert Rev Endocrinol Metab. 2010;5(3):331-342. Metformin also forms the cornerstone of dual therapy and is used extensively in combination with several classes of OADs. The safety and efficacy of ...
The fixed-duration treatment of ICP-248 in combination with orelabrutinib will provide deeper remission for treatment-naïve CLL/SLL patients without drug-resistant mutations, bringing hope of ...
Traditionally, the approach is to initiate monotherapy first, followed by combination therapy that targets two main defects in T2DM. Repaglinide, a rapidly acting insulin secretagog, stimulates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback